Navigation Links
Interrupted Treatment Dangerous to HIV Management

A recent research keenly studied the effect of discontinuing HIV drug therapy and then restarting it as and when required. The results can be positively// devastating, reported the study. New England Journal of Medicine has published the results of this current research in its Nov 30 issue. If the treatment is discontinued, the patients face a greater chance of developing full blown AIDS and also suffer from toxic side effects of the anti retro viral drugs that are used for treatment.

In the initial days when antiretroviral drugs were introduced for the first time, ARV drugs helped to control HIV infection in a big way. However, these drugs are known to cause grave side effects, such as complications related to the heart and metabolic functions. The treatment is also quite exorbitant and difficult to abide by. Resistant viral strains may also develop as a result of anti retroviral treatment.

However, in spite of all the odds tossed against it, it’s safer for a HIV infected person any day to be continuously on ARV treatment than, stopping treatment.

At one point of time, doctors had indeed speculated on calling for a time out in between treatment. But not any more.

Dr. Roy Gulick, director of the HIV Clinical Trials Unit, appended to Weill Cornell Medical College, New York, explained that the levels of the virus is kept suppressed only when the ARV drugs are regularly taken without any break, whatsoever. Other wise, the patient will inevitably have to suffer unexpected relapses and complications. The research, that was intended to span over a period of 6 years was called off after 16 months as the dangers were too high for the group of HIV infected volunteers that were given doses of ARV drugs, intermittently. Unlike what doctors had presumed, the chances of cardiovascular, liver and kidney diseases increased. These diseases were previously considered as side effects. Actually absence of treatment opens up the risk even more.'"/>




Page: 1 2

Related medicine news :

1. Its Never too Late to Get It Back! Aging Interrupted
2. Advances in Treatment of Cataracts
3. Recommendations for Treatment of Blood Pressue
4. Treatment for Menieres disease
5. Treatment for pre-menstrual syndrome is ineffective
6. Better Treatment for obesity
7. Gene Treatment for Heart Disease
8. More People Seeking Treatment for Depression
9. Focused Treatment For Childhood Cancer
10. Inadequate Drug Treatment For Youth
11. FDA Approves New surgery Treatment for Farsightedness
Post Your Comments:
Breaking Medicine News(10 mins):Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 2Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 3Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 4Health News:Procter & Gamble Announces Appointment of Director 2Health News:Possible ovarian cancer treatment target identified 2Health News:Testosterone Gets Bad Rap: Study 2Health News:Testosterone Gets Bad Rap: Study 3Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 2Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 3Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 4Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 5Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 6Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 7Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 8Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 9Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 10Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 11Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 12Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 13Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 14Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 15Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 16Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 17Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 18Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 19Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 20Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 21
Breaking Medicine Technology:Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 2Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 3Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 4Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 5Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 6Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 7Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 8Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 9Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 2Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 3Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 4Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 5Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 6Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 7Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 2Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 3Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 4Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 5Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 6Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 7Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 8Members of National CHD Organization Unite for Little Hearts Celebration and Assemble for Picture of Hope 48154 1Members of National CHD Organization Unite for Little Hearts Celebration and Assemble for Picture of Hope 48154 2Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex 28Ferric Citrate 29 for the Treatment of Hyperphosphatemia in End Stage Re 12516 1Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex 28Ferric Citrate 29 for the Treatment of Hyperphosphatemia in End Stage Re 12516 2Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex 28Ferric Citrate 29 for the Treatment of Hyperphosphatemia in End Stage Re 12516 3Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex 28Ferric Citrate 29 for the Treatment of Hyperphosphatemia in End Stage Re 12516 4Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex 28Ferric Citrate 29 for the Treatment of Hyperphosphatemia in End Stage Re 12516 5Intarcia Therapeutics Inc Presents ITCA 650 Phase 1b Study Results as a Late Breaker at the American Diabetes Association 69th Scientific Sessions 12513 1Intarcia Therapeutics Inc Presents ITCA 650 Phase 1b Study Results as a Late Breaker at the American Diabetes Association 69th Scientific Sessions 12513 2Intarcia Therapeutics Inc Presents ITCA 650 Phase 1b Study Results as a Late Breaker at the American Diabetes Association 69th Scientific Sessions 12513 3Intarcia Therapeutics Inc Presents ITCA 650 Phase 1b Study Results as a Late Breaker at the American Diabetes Association 69th Scientific Sessions 12513 4